Market Closed -
Nyse
16:01:36 2024-04-26 EDT
|
5-day change
|
1st Jan Change
|
25.4
USD
|
+0.55%
|
|
-2.31%
|
-11.77%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
216,827
|
204,605
|
331,440
|
287,626
|
162,560
|
143,829
|
-
|
-
|
Enterprise Value (EV)
1 |
259,147
|
232,220
|
338,807
|
300,723
|
221,758
|
190,866
|
185,740
|
179,763
|
P/E ratio
|
13.7
x
|
21.5
x
|
15.3
x
|
9.37
x
|
77.8
x
|
18.7
x
|
13.6
x
|
12.4
x
|
Yield
|
3.68%
|
4.13%
|
2.64%
|
3.14%
|
5.73%
|
6.68%
|
6.85%
|
6.94%
|
Capitalization / Revenue
|
4.19
x
|
4.88
x
|
4.08
x
|
2.87
x
|
2.78
x
|
2.4
x
|
2.3
x
|
2.27
x
|
EV / Revenue
|
5.01
x
|
5.54
x
|
4.17
x
|
3
x
|
3.79
x
|
3.18
x
|
2.97
x
|
2.84
x
|
EV / EBITDA
|
12.3
x
|
13
x
|
13.3
x
|
7.1
x
|
14.2
x
|
9.64
x
|
8.2
x
|
7.63
x
|
EV / FCF
|
24.9
x
|
19.1
x
|
11.3
x
|
11.6
x
|
46.3
x
|
19.6
x
|
12.6
x
|
11.1
x
|
FCF Yield
|
4.02%
|
5.23%
|
8.82%
|
8.66%
|
2.16%
|
5.1%
|
7.92%
|
9.01%
|
Price to Book
|
3.43
x
|
3.24
x
|
4.3
x
|
3
x
|
1.83
x
|
1.65
x
|
1.64
x
|
1.62
x
|
Nbr of stocks (in thousands)
|
5,534,122
|
5,558,397
|
5,612,867
|
5,613,315
|
5,646,413
|
5,662,541
|
-
|
-
|
Reference price
2 |
39.18
|
36.81
|
59.05
|
51.24
|
28.79
|
25.40
|
25.40
|
25.40
|
Announcement Date
|
20-01-28
|
21-02-02
|
22-02-08
|
23-01-31
|
24-01-30
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
51,750
|
41,908
|
81,288
|
100,330
|
58,496
|
59,955
|
62,567
|
63,284
|
EBITDA
1 |
21,097
|
17,801
|
25,426
|
42,336
|
15,590
|
19,802
|
22,661
|
23,561
|
EBIT
1 |
19,420
|
13,024
|
20,235
|
37,272
|
9,300
|
16,364
|
19,064
|
19,964
|
Operating Margin
|
37.53%
|
31.08%
|
24.89%
|
37.15%
|
15.9%
|
27.29%
|
30.47%
|
31.55%
|
Earnings before Tax (EBT)
1 |
17,682
|
7,497
|
24,311
|
34,729
|
1,058
|
9,561
|
13,702
|
12,097
|
Net income
1 |
16,273
|
9,616
|
21,979
|
31,372
|
2,119
|
6,746
|
9,289
|
10,111
|
Net margin
|
31.45%
|
22.95%
|
27.04%
|
31.27%
|
3.62%
|
11.25%
|
14.85%
|
15.98%
|
EPS
2 |
2.870
|
1.710
|
3.850
|
5.470
|
0.3700
|
1.362
|
1.874
|
2.054
|
Free Cash Flow
1 |
10,412
|
12,151
|
29,869
|
26,031
|
4,793
|
9,742
|
14,711
|
16,190
|
FCF margin
|
20.12%
|
28.99%
|
36.74%
|
25.95%
|
8.19%
|
16.25%
|
23.51%
|
25.58%
|
FCF Conversion (EBITDA)
|
49.35%
|
68.26%
|
117.47%
|
61.49%
|
30.74%
|
49.2%
|
64.92%
|
68.71%
|
FCF Conversion (Net income)
|
63.98%
|
126.36%
|
135.9%
|
82.98%
|
226.19%
|
144.41%
|
158.38%
|
160.13%
|
Dividend per Share
2 |
1.440
|
1.520
|
1.560
|
1.610
|
1.650
|
1.696
|
1.739
|
1.763
|
Announcement Date
|
20-01-28
|
21-02-02
|
22-02-08
|
23-01-31
|
24-01-30
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
24,094
|
23,838
|
25,661
|
27,742
|
22,638
|
24,290
|
18,282
|
12,734
|
13,232
|
14,249
|
13,923
|
13,125
|
15,077
|
17,812
|
15,680
|
EBITDA
1 |
9,876
|
4,403
|
11,135
|
13,583
|
10,325
|
6,772
|
7,857
|
4,925
|
-1,244
|
1,340
|
4,403
|
4,126
|
5,359
|
4,754
|
-
|
EBIT
1 |
8,516
|
3,126
|
9,948
|
12,408
|
9,142
|
5,253
|
6,370
|
3,319
|
-1,625
|
-330
|
3,667
|
3,343
|
4,305
|
4,999
|
-
|
Operating Margin
|
35.34%
|
13.11%
|
38.77%
|
44.73%
|
40.38%
|
21.63%
|
34.84%
|
26.06%
|
-12.28%
|
-2.32%
|
26.34%
|
25.47%
|
28.55%
|
28.07%
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-
|
9,050
|
-
|
-
|
5,231
|
-
|
-
|
-3,352
|
-4,129
|
2,992
|
2,061
|
2,651
|
3,182
|
-
|
Net income
1 |
8,146
|
3,393
|
7,864
|
9,906
|
8,608
|
4,995
|
5,543
|
2,327
|
-2,382
|
-3,369
|
1,951
|
1,265
|
2,156
|
3,135
|
-
|
Net margin
|
33.81%
|
14.23%
|
30.65%
|
35.71%
|
38.02%
|
20.56%
|
30.32%
|
18.27%
|
-18%
|
-23.64%
|
14.01%
|
9.64%
|
14.3%
|
17.6%
|
-
|
EPS
2 |
1.420
|
0.5900
|
1.370
|
1.730
|
1.510
|
0.8700
|
0.9700
|
0.4100
|
-0.4200
|
-0.6000
|
0.3416
|
0.2331
|
0.4250
|
0.5533
|
-
|
Dividend per Share
2 |
0.3900
|
0.3900
|
0.4000
|
0.4000
|
0.4000
|
0.4100
|
0.4100
|
0.4100
|
0.4100
|
0.4200
|
0.4109
|
0.4109
|
0.4109
|
0.4109
|
0.4220
|
Announcement Date
|
21-11-02
|
22-02-08
|
22-05-03
|
22-07-28
|
22-11-01
|
23-01-31
|
23-05-02
|
23-08-01
|
23-10-31
|
24-01-30
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
42,320
|
27,615
|
7,367
|
13,097
|
59,198
|
47,037
|
41,911
|
35,934
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
2.006
x
|
1.551
x
|
0.2897
x
|
0.3094
x
|
3.797
x
|
2.375
x
|
1.849
x
|
1.525
x
|
Free Cash Flow
1 |
10,412
|
12,151
|
29,869
|
26,031
|
4,793
|
9,742
|
14,711
|
16,190
|
ROE (net income / shareholders' equity)
|
25.7%
|
15.2%
|
31.3%
|
43.5%
|
11.4%
|
12.4%
|
15.5%
|
15.9%
|
ROA (Net income/ Total Assets)
|
9.96%
|
5.98%
|
13.1%
|
19.9%
|
4.96%
|
4.39%
|
5.8%
|
6.43%
|
Assets
1 |
163,456
|
160,910
|
167,853
|
157,490
|
42,750
|
153,543
|
160,234
|
157,232
|
Book Value Per Share
2 |
11.40
|
11.40
|
13.70
|
17.10
|
15.80
|
15.30
|
15.50
|
15.70
|
Cash Flow per Share
2 |
2.220
|
2.560
|
5.710
|
5.110
|
1.520
|
2.800
|
3.630
|
3.750
|
Capex
1 |
2,176
|
2,252
|
2,711
|
3,236
|
3,907
|
2,897
|
2,912
|
2,937
|
Capex / Sales
|
4.2%
|
5.37%
|
3.34%
|
3.23%
|
6.68%
|
4.83%
|
4.65%
|
4.64%
|
Announcement Date
|
20-01-28
|
21-02-02
|
22-02-08
|
23-01-31
|
24-01-30
|
-
|
-
|
-
|
Last Close Price
25.4
USD Average target price
31.62
USD Spread / Average Target +24.49% Consensus |
1st Jan change
|
Capi.
|
---|
| -11.77% | 144B | | +25.83% | 661B | | +27.00% | 566B | | -6.76% | 352B | | +20.34% | 332B | | +3.00% | 283B | | +13.09% | 231B | | +5.46% | 200B | | -9.61% | 195B | | -6.26% | 145B |
Other Pharmaceuticals
|